Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

(1) Background: Citrate is preferred in continuous renal replacement therapy (CRRT) for critically ill patients because it prolongs filter life and reduces bleeding risks compared to unfractionated heparin (UFH). However, regional citrate anticoagulation (RCA) can lead to acid–base disturbances, cit...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Rita Jacobs, Walter Verbrugghe, Jason Bouziotis, Ingrid Baar, Karolien Dams, Annick De Weerdt, Philippe G. Jorens
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: MDPI AG 2024-10-01
Cyfres:Life
Pynciau:
citrate anticoagulation
heparin
renal replacement therapy
filter lifespan
bleeding
acid–base disturbances
Mynediad Ar-lein:https://www.mdpi.com/2075-1729/14/10/1304

Rhyngrwyd

https://www.mdpi.com/2075-1729/14/10/1304

Eitemau Tebyg